CLINICAL TRIALS PROFILE FOR TREPROSTINIL DIOLAMINE
✉ Email this page to a colleague
All Clinical Trials for treprostinil diolamine
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01560624 ↗ | Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy | Completed | United Therapeutics | Phase 3 | 2012-06-26 | This is an international, multicenter, randomized, double-blind, placebo-controlled, event driven study in subjects with pulmonary arterial hypertension. |
| NCT01746485 ↗ | Three Times Daily Dosing of UT-15C | Completed | United Therapeutics | Phase 1 | 2012-07-01 | To evaluate the pharmacokinetics of three-times daily dosing of UT-15C in healthy volunteers |
| NCT02663895 ↗ | Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis | Completed | United Therapeutics | Phase 2 | 2016-10-01 | This is a prospective open-label trial that will enroll 12 patients with systemic sclerosis (SSc) and at least one calcinotic lesion of the hands that is palpable on physical examination and also measureable on hand radiographs, at one single center. Each subject will receive treprostinil orally for 12 months, and follow-up evaluations will be performed every 3 months. Our main objective is to determine whether oral treprostinil is safe, and effective in reducing calcinosis in patients with SSc. We hypothesize that calcinosis is a result of microvascular injury and ischemic damage, and that therefore treprostinil may be beneficial in the treatment of calcinosis in patients with SSc. |
| NCT02663895 ↗ | Safety and Efficacy of Oral Treprostinil in the Treatment of Calcinosis in Patients With Systemic Sclerosis | Completed | Stanford University | Phase 2 | 2016-10-01 | This is a prospective open-label trial that will enroll 12 patients with systemic sclerosis (SSc) and at least one calcinotic lesion of the hands that is palpable on physical examination and also measureable on hand radiographs, at one single center. Each subject will receive treprostinil orally for 12 months, and follow-up evaluations will be performed every 3 months. Our main objective is to determine whether oral treprostinil is safe, and effective in reducing calcinosis in patients with SSc. We hypothesize that calcinosis is a result of microvascular injury and ischemic damage, and that therefore treprostinil may be beneficial in the treatment of calcinosis in patients with SSc. |
| NCT04882774 ↗ | Telemonitoring to Treat Group 2 Pulmonary Hypertension | Not yet recruiting | Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | Phase 2 | 2022-04-01 | This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in combination with the fluid management plan while those with improved pressures maintain their fluid management plan for an additional 16 weeks. |
| NCT04882774 ↗ | Telemonitoring to Treat Group 2 Pulmonary Hypertension | Not yet recruiting | Ohio State University | Phase 2 | 2022-04-01 | This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in combination with the fluid management plan while those with improved pressures maintain their fluid management plan for an additional 16 weeks. |
| NCT04882774 ↗ | Telemonitoring to Treat Group 2 Pulmonary Hypertension | Not yet recruiting | Mardi Gomberg -Maitland | Phase 2 | 2022-04-01 | This study aims to decrease elevated pressure in the lungs of patients with pulmonary hypertension from left heart with elevated pulmonary vascular resistance by utilizing aggressive fluid management with ReDS Pro System and CardioMEMS device. Participants with persistently elevated pulmonary pressure at Week 16 will begin oral treprostinil in combination with the fluid management plan while those with improved pressures maintain their fluid management plan for an additional 16 weeks. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for treprostinil diolamine
Condition Name
Clinical Trial Locations for treprostinil diolamine
Trials by Country
Clinical Trial Progress for treprostinil diolamine
Clinical Trial Phase
Clinical Trial Sponsors for treprostinil diolamine
Sponsor Name
| Sponsor Name for treprostinil diolamine | |
| Sponsor | Trials |
| United Therapeutics | 3 |
| Stanford University | 1 |
| Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) | 1 |
| [disabled in preview] | 2 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
